Bosutinib Inhibits EGFR Activation in Head and Neck Cancer

Bosutinib Inhibits EGFR Activation in Head and Neck Cancer

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide, and although new therapeutic approaches have been recently evaluated, overall patient survival is still poor. Thus, new effective and selective clinical treatments are urgently needed. An analysis of data from l...

Full description

Bibliographic Details
Main Authors: Carmen Segrelles, David Contreras, Elena M. Navarro, Carmen Gutiérrez-Muñoz, Ramón García-Escudero, Jesús M. Paramio, Corina Lorz
Format: Article
Language:English
Published: MDPI AG 2018-06-01
Series:International Journal of Molecular Sciences
Subjects:
head and neck cancer
targeted therapies
EGFR inhibitors
Bosutinib
Alpelisib
cancer cell lines
Online Access:http://www.mdpi.com/1422-0067/19/7/1824

Internet

http://www.mdpi.com/1422-0067/19/7/1824

Similar Items